share_log

InMed Pharmaceuticals | 10-Q: Q1 2025 Earnings Report

InMed Pharmaceuticals | 10-Q: Q1 2025 Earnings Report

InMed Pharmaceuticals | 10-Q：2025財年一季報
美股SEC公告 ·  2024/11/15 05:22

Moomoo AI 已提取核心訊息

InMed Pharmaceuticals reported financial results for Q1 fiscal 2025 ended September 30, 2024. Revenue increased 40% YoY to $1.26 million, driven by expanded marketing efforts and higher demand for certain cannabinoid products. Net loss narrowed to $1.68 million from $2.54 million a year ago. Gross profit surged to $493,413 from $21,242 in Q1 2024.Research and development expenses decreased 40% to $771,180 due to lower external contractor and patent costs. General and administrative expenses rose 16% to $1.42 million on higher investor relations and personnel expenses. The company ended the quarter with $5.58 million in cash and cash equivalents.InMed provided updates on its pharmaceutical pipeline, including positive preclinical results for INM-901 in Alzheimer's disease. The company effected a 1-for-20 reverse stock split in November to regain Nasdaq compliance. Management expects current cash to fund operations into Q1 calendar 2025, depending on BayMedica revenue realization and expense levels.
InMed Pharmaceuticals reported financial results for Q1 fiscal 2025 ended September 30, 2024. Revenue increased 40% YoY to $1.26 million, driven by expanded marketing efforts and higher demand for certain cannabinoid products. Net loss narrowed to $1.68 million from $2.54 million a year ago. Gross profit surged to $493,413 from $21,242 in Q1 2024.Research and development expenses decreased 40% to $771,180 due to lower external contractor and patent costs. General and administrative expenses rose 16% to $1.42 million on higher investor relations and personnel expenses. The company ended the quarter with $5.58 million in cash and cash equivalents.InMed provided updates on its pharmaceutical pipeline, including positive preclinical results for INM-901 in Alzheimer's disease. The company effected a 1-for-20 reverse stock split in November to regain Nasdaq compliance. Management expects current cash to fund operations into Q1 calendar 2025, depending on BayMedica revenue realization and expense levels.
InMed Pharmaceuticals發佈了截至2024年9月30日的2025財年第一季度財務業績。營業收入同比增長40%，達到126萬美元，主要得益於營銷工作的擴展和對某些大麻素產品需求的增加。淨虧損從去年同期的254萬美元縮減至168萬美元。毛利潤從2024年第一季度的21,242美元激增至493,413美元。研究與開發費用由於外部承包商和專利費用降低而減少40%，爲771,180美元。由於投資者關係和人員費用增加，管理和行政費用上升16%，達到142萬美元。該公司在季度末擁有558萬美元的現金及現金等價物。InMed提供了其藥品管線的更新，包括INm-901在阿爾茨海默病方面的積極前期臨牀結果。爲了恢復納斯達克合規性，該公司在11月進行了1比20的反向股票拆分。管理層預計目前的現金能夠支持運營到2025年第一季度，具體取決於BayMedica的營業收入實現及費用水平。
InMed Pharmaceuticals發佈了截至2024年9月30日的2025財年第一季度財務業績。營業收入同比增長40%，達到126萬美元，主要得益於營銷工作的擴展和對某些大麻素產品需求的增加。淨虧損從去年同期的254萬美元縮減至168萬美元。毛利潤從2024年第一季度的21,242美元激增至493,413美元。研究與開發費用由於外部承包商和專利費用降低而減少40%，爲771,180美元。由於投資者關係和人員費用增加，管理和行政費用上升16%，達到142萬美元。該公司在季度末擁有558萬美元的現金及現金等價物。InMed提供了其藥品管線的更新，包括INm-901在阿爾茨海默病方面的積極前期臨牀結果。爲了恢復納斯達克合規性，該公司在11月進行了1比20的反向股票拆分。管理層預計目前的現金能夠支持運營到2025年第一季度，具體取決於BayMedica的營業收入實現及費用水平。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間